Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Celldex culls eczema study after Phase 2 failure

Celldex Therapeutics is dropping its monoclonal antibody as a therapy for eczema after the drug flunked a mid-stage study. The drug, called barzolvolimab, failed to reduce itching in patients with eczema compared with placebo after ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 20 November →